Erectile Dysfunction: Causes And Treatments — Dr. Mark Hackman — UHC TV

http://www.uhc.tv Men’s health expert Dr. Mark Hackman discusses erectile dysfunction (ED), its physical and psychological causes, and treatment options. To …
Video Rating: 0 / 5

http://penislarge.freeus86.com or http://www.artsina.com/impotent — The Conventional Causes Of Erectile Dysfunction Hormonal Imbalances… while testosteron…
Video Rating: 0 / 5

FDA Notifies Not to Use MV5 Days: AttorneyOne Monitor and Keep Consumers Informed


San Diego, CA (PRWEB) May 22, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for MV5 Days.

The FDA notified consumers on May 16, not to purchase or use MV5 Days because it contains sildenafil. MV5 Days is promoted as a product for sexual enhancement.

Sildenafil is the active ingredient in Viagra, the FDA approved prescription drug used to treat erectile dysfunction. This ingredient may interact with nitrates found in certain drugs used to treat heart disease, high blood pressure and diabetes and can lower blood pressure to dangerous levels.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds we are determined to keep an eye on FDA announcements concerning MV5 Days and inform the public. For that reason”, he continues, “our focus should squarely fall on investigating these safety alerts and getting the word out.

As the FDA advises Do not purchase or use MV5 Days.

AttorneyOne.com has further information on MV5 Days at the website including latest major drug and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/05/prweb11871885.htm







New BPH Treatment User Feedback from Madrid, Spain Confirms the Effectiveness of Dr. Allen’s Device for Prostate Care


London, UK (PRWEB) June 19, 2014

Fine Treatment is pleased to share a new BPH treatment success story coming from Madrid, Spain. Charles O., 60, a user of Dr. Allens Device for Prostate Care, provided 2 feedback reports: the first one came after 3 months of using the device, and the second one was sent after the total treatment period of 6 months. In essence, the use of Dr. Allens Device has reduced enlarged prostate in size, gradually relieving the troubling BPH symptoms and markedly improving the quality of life.

On April 19, 2014, Fine Treatment received an email from Charles saying, Big thanks to Dr. Simon Allen for his wonderful device. I started to wear this device since January 14, 2014. Now, after 3 months, practically all the bad symptoms are gone. I only feel a little urgency to urinate. I enjoy my life again. I wish that all men would know about this device. Once more, thank you sir.

On June 10, 2014, Charles wrote, An ultrasound report, dated June 2, 2014, shows that the prostate size has become normal in comparison with the one from December 2013. It is really amazing. I sleep well all the night now, wakening up to urinate once or none.

Ill be happy to be interviewed by journalists and I can show them all my analyses and ultrasound report, adds Charles.

Fine Treatment works hard to disseminate treatment knowledge. Thermobalancing therapy is a superior treatment method enabled by Dr. Allens Devices. Fine Treatment does its best to make this natural treatment available internationally.

At the same time, recent articles in The Jewish Voice and Trinidad Express have reported issues with taking prostate medications, a common BPH treatment method which, however, is likely to cause nasty side effects.

The Jewish Voice article on Enlarged Prostate: What is it? What are the treatments? dated June 18, 2014, states: Alpha reductase inhibitors, Avodart or Proscar, reduce the size of the prostate, thus reducing the pressure on the urethra. Often, improvements are not seen for a couple of weeks or even months. Common side effects include decreased sex drive and erectile dysfunction.

Another article titled Doc, what to do about this BPH? in the Trinidad Express, of May 25, 2014, warns, It is important to note that one side effect of Alpha Blockers is they can lower your blood pressure causing dizziness that could lead to falls.

Fine Treatment is active in monitoring customer treatment progress. Here you can watch a short video: http://www.youtube.com/watch?v=V5xidswhxJM where a man has shrunk enlarged prostate by wearing Dr. Allens Device for 2 years without any medications.

Fine Treatments customer base stretches over 100 countries around the globe, notes Dr. Simon Allen. We do our best to help people to improve their health wherever they are. This new user report confirms the amazing effectiveness of therapeutic Dr. Allens Device and treatment method which cleanses the prostate gland and relieves nasty BPH symptoms naturally.

For details, visit Fine Treatment at http://finetreatment.com/bph-treatment-prostate-enlargement.

About Dr. Simon Allen and Fine Treatment:

Dr. Simon Allen, MD, PhD, Academician, member of the ATA, is a highly experienced medical professional. He specializes in internal medicine. He has treated a wide range of chronic diseases, including patients after a heart attack, with kidneys problems, including kidney stones disease, prostate and spine conditions, as well as metabolic disorders.

Fine Treatment supports global customer outreach, and ensures international availability of Dr. Allens Devices for the treatment of chronic prostatitis and BPH, coronary heart disease, for dissolving kidney stones, as well as for easing headaches, dizziness, and relieving lower back pain and sciatica.







Find More Erectile Dysfunction Press Releases

Beaumont First in U.S. to Treat Prostate Cancer with MRI-Guided Ultrasound Therapy


Royal Oak, MI (PRWEB) February 20, 2014

Urologists at Beaumont Hospital, Royal Oak are first in the U.S. to treat localized prostate cancer with a transurethral ultrasound therapy guided by magnetic resonance imaging. The experimental treatment is designed to potentially reduce the long-term complications of traditional prostate cancer treatments.

The first treatment on Jan. 25 marked the launch of the Transurethral Ultrasound Ablation research study at Beaumont evaluating the safety and effectiveness of a new medical device developed by Profound Medical Inc. of Canada.

The new, single treatment, outpatient procedure uses MRI guidance to allow physicians to precisely target the delivery of thermal (heat) therapy to the prostate gland with an ultrasound device inserted in the urethra. Ultrasound is a procedure in which high-energy sound waves are aimed directly at an area of abnormal cells or tissue in the body. The waves create heat that kills cells. The direct targeting with MRI is designed to spare nearby nerves and organs, such as the bladder, rectum and colon, from damage, potentially reducing treatment side effects.

Traditional prostate cancer treatments – surgery and radiation therapy – provide good local control of the disease, but can leave men with significant long-term complications affecting urinary, bowel and sexual function, says James Relle, M.D., urologist and co-principal investigator of the Beaumont study. These issues can significantly reduce a patients quality of life.

A better understanding of the natural history of prostate cancer has led us to focus on less invasive or less radical treatments, says Jason Hafron, M.D., urologist, and co-principal investigator of the study. As more men are diagnosed with prostate cancer through earlier screening and detection, we are focusing on development of treatment options with fewer long-term complications affecting quality of life.

To be eligible for the study, patients must meet criteria, including:

Be a male, 65 years of age or older
Have low-risk, early-stage, organ-confined prostate cancer
Be eligible for magnetic resonance imaging
Able to tolerate general anesthesia
Have biopsy confirmed cancer of the prostate
Not have a bleeding disorder
Not have a latex allergy
Not have a history of any major rectal or pelvic surgery
Not currently treated with antidepressant drugs

Research participants will be followed for a minimum of 12 months, including monitoring of quality of life and for signs of cancer recurrence.

For more information on study enrollment, call Maureen Cooney at 248-551-9477.

According to the American Cancer Society, prostate cancer is the most prevalent cancer in American men. About one man in six will be diagnosed with prostate cancer during his lifetime, with the risk being highest after age 60. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. About 1 man in 36 will die of prostate cancer.

Prostate cancer forms in tissues of the prostate, a gland in the male reproductive system found below the bladder and in front of the rectum. The prostate surrounds the urethra, the tube through which urine flows. A healthy prostate is about the size of a walnut. If the prostate grows too large, it squeezes the urethra. This may slow or stop the normal flow of urine.

About Beaumont Urology

Beaumont urologists offer endoscopic, robotic and laparoscopic surgical options as well as traditional surgeries. They also specialize in treatment for kidney stones; painful bladder conditions such as overactive bladder and incontinence; sexual dysfunction; urologic cancer; prostate conditions; male infertility; voiding dysfunction; and erectile dysfunction. In 2010, Beaumont opened a Womens Urology Center, the first center in the Midwest dedicated and designed for womens urological care and sexual dysfunction. Beaumont, Royal Oak is ranked on U.S. News & World Reports Americas Best Hospitals list for urology. Find out more at http://www.beaumont.edu/urology.

# # #







What happens when you go to the doctor and say you can't get an erection

What happens when you go to the doctor and say you can't get an erection
It is estimated that only a third of men with erectile dysfunction seek treatment. This is what happens if you do. by David Vernon Published 17 June, 2014 – 09:18. StumbleUpon logo Reddit logo Print HTML logo Facebook LikeGoogle Plus OneTweet Widget.
Read more on New Statesman

Nike named the most counterfeited brand, but statistics don't give the full
… in particular industries – last year, for instance, a number of pharmaceutical campaigns were undertaken, which could account for the difference in cases involving erectile dysfunction treatment Cialis across 2012 (1,604 cases in 2012 versus 525 in …
Read more on World Trademark Review (subscription)

High Blood Pressure Treatment
In some rare cases, diuretics can cause gout attacks and erectile dysfunction. Beta-blockers. These drugs are used for treating a number of conditions, such as: hypertension, angina, asthma, chronic obstructive pulmonary disease, etc. They slow down …
Read more on Doctor Tipster

Global Human Reproductive Technologies Market: Analysis, Size, Procedures, Growth, Trends and Forecast 2013 – 2019


Albany, New York (PRWEB) May 21, 2014

Human Reproductive Technologies Market was valued at USD 23.0 billion in 2012 and is expected to reach USD 27.1 billion in 2019, growing at a CAGR of 2.2% from 2013 to 2019.

Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Lack of awareness about the reproductive deficiencies and their treatment necessity and availability has been limiting the market to explore its potential value. Therefore, awareness strategies adopted by market players with proper guidance for patients will fuel the emerging human reproductive technologies market especially the infertility treatment market. Developing regions such as the Asia-Pacific, Latin America, Africa and Middle-East hold the maximum growth potential in the human reproductive technologies market. Some of the other factors contributing to the growth of human reproductive technologies market include delay in conceiving, lifestyle habits such as smoking, excessive alcohol consumption, increasing use of contraceptive pills and devices, and rising incidences of infertility.

Browse Global Human Reproductive Technologies Market Report with Full TOC: http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

The infertility treatment market is characterized by the presence of many leading patented drug brands which are restraining the entry of generics and hence, creating a monopolistic situation. In addition, due to patient sentiments attached to infertility treatment procedures, risk ofno conception due to a low-quality generic drugis usually avoided. This report includes market analysis for seven major (by sales) branded formulations of infertility drugs, namely, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Similarly, the contraceptive drugs and devices market has many drugs in the research pipeline awaiting commercialization to grab a share of this potential market. Large and well established pharmaceutical players such as Merck Serono, Merck & Co., Inc., Bayer AG, Pfizer, Inc., Actavis plc, Ferring International Center S.A. and Teva Pharmaceutical Industries Ltd. dominate the human reproductive technologies market.

The global contraceptives market was valued at USD 16.0billion in 2012 and is expected to grow at a CAGR of 5.5% from 2013 to 2019. The oral contraceptive pills market lead the overall contraceptives market in 2012 in terms of revenue, mainly due to increasing population awareness through advertisements enabling patients to buy them over-the-counter. In the contraceptive devices market, male condoms formed the largest market segment owing to the increased accessibility and awareness along with their ease of use.

The infertility drugs market studied in this report include leading brands from three drug classes, namely, gonadotropins, androgens and erectile dysfunction drugs. Among these, Viagra was the largest brand by revenue in 2012 among others considered in the study due to increasing cases of erectile dysfunction in male infertility. Moreover, it has been a well-established and popular brand since its approval in 1998 by the U.S. FDA. Gonal-f in the gonadotropin class is the leading brand prescribed by majority of the infertility specialist due to better results achieved using it. For testosterone deficiency which is one of the major infertility causes in male patients, AndroGel is the blockbuster drug being preferred for the treatment. Generic manufacturers such as Watson Pharmaceuticals and Par Pharmaceuticals are expected to enter the market with their generic versions by 2015.

Among the infertility procedures, intrauterine insemination (IUI) is the most preferred treatment procedure due to its low operational cost and equal success rate compared to intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), which follow IUI in terms of preference. The simplicity of performing IUI is what attracts the healthcare professionals to prefer this procedure over others. Zygote intrafallopian transfer (ZIFT) and gamete intrafallopian transfer (GIFT) are the least popular procedures performed worldwide, accounting for about 0.1% of the total ART treatments. This is due to the higher procedural costs and complexity in performing these procedures.

Related & Recently Published Reports by Transparency Market Research

Microserver Market: http://www.transparencymarketresearch.com/microserver-market.html
Infusion Pumps Market: http://www.transparencymarketresearch.com/infusion-systems-market.html

North America dominated the global human reproductive technologies market in 2012 and is expected to maintain its leading market position till 2019. However, the Asia-Pacific contraceptive technologies market is estimated to grow at a faster pace (CAGR of 6.9% from 2013 to 2019) mainly to the rising awareness and acceptance of reproductive technologies in this region. Entry of large market players such as Merck Serono, Ferring International Center S.A. and Merck & Co., Inc.will also drive the market in the Asia-Pacific region.

Some of the key players in the global human reproductive technologies market include Abbott Laboratories, Bayer AG, Merck & Co., Inc., Merck Serono, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Watson Pharmaceuticals and Reckitt Benckiser.

Browse Global Human Reproductive Technologies Market Report with Full TOC: http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

The global human reproductive technologies market is categorized into the following segments:

Human Reproductive Technologies Market, by Infertility Drugs

Gonal-f (recombinant follitropin alfa)
Follistim AQ (follitropin beta)
AndroGel (testosterone)
Testim (testosterone)
Viagra (sildenafil citrate)
Cialis (tadalafil)
Levitra/Staxyn (vardenafil)

Human Reproductive Technologies Market, by Infertility Procedures

In Vitro Fertilization (IVF)
Intracytoplasmic Sperm Injection (ICSI)
Zygote Intrafallopian Transfer (ZIFT)
Gamete Intrafallopian Transfer (GIFT)
Intrauterine Insemination (IUI)

Human Reproductive Technologies Market, by Contraceptive Technologies

Drugs

Oral Contraceptive Pills
Contraceptive Injectables
Topical Contraceptives

Devices

Male Contraceptive Devices (Male Condoms)
Female Contraceptive Devices
Female Condoms
Diaphragms
Sponges
IUDs
Hormonal IUDs
Copper IUDs
Subdermal Contraceptive Implants
Vaginal Rings

Human Reproductive Technologies Market,by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse Global Human Reproductive Technologies Market Report with Full TOC: http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html







Find More Erectile Dysfunction Medications Press Releases

Potent drug 'Fly High' now in Cebu?

Potent drug 'Fly High' now in Cebu?
“Fly High” is a capsule containing a mixture of ecstasy, shabu (methamphetamine) and cialis, an ingredient found in drugs used to treat erectile dysfunction such as Viagra. It is said … erection. Like other illegal drugs, an overdose may cause the …
Read more on Sun.Star

Health Notes: Posh races ahead of bootcamp rivals – and doesn't even need to
And a pilot study detailed in the International Journal of Impotence Research showed that the juice may have benefits for men with erectile dysfunction and impotence. Now the new trials are taking place at the University of … The authors believe the …
Read more on Daily Mail

8 dangerous habits of careless people
Cholesterol is also a leading cause of gallstones. Also, enjoy eating … That is, it increases your risk of developing diseases, such as cirrhosis (liver damage), damage to the pancreas, certain cancers, heart problems sexual problems, and other …
Read more on Business Mirror